Clinical Presentations, Management and Outcomes of Rhino-Orbital-Cerebral Mucormycosis (ROCM) Following COVID-19: A Multi-Centric Study
Open Access
- 27 July 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 37 (5) , 488-495
Abstract
Purpose: To report clinical presentations and factors affecting outcomes in rhino-orbital-cerebral mucormycosis following COVID-19. Methods: Retrospective multi-centric interventional case series of 58 eyes with rhino-orbital-cerebral mucormycosis. Demography, clinical parameters and management outcomes were noted. Factors affecting outcome and mortality were analyzed. Outcome was defined as favorable when complete resolution or stabilization without further progression of the infection was noted at last visit. Results: Mean age was 55 ± 11 years (median 56). The mean HbA1c value was 10.44 ± 2.84 mg% (median 10.5). The duration between the diagnosis of COVID-19 and rhino-orbital-cerebral mucormycosis was 16 ± 21 days (median: 8 days). Thirty-six eyes (62%) had no vision at presentation. Imaging revealed paranasal sinus involvement (100%), orbital apex involvement (41%), cavernous sinus involvement (30%), and central nervous system (CNS) involvement (33%). All the patients were treated with systemic Liposomal amphotericin-B and sinus debridement. Twenty-two eyes (38%) underwent exenteration. One eye underwent transcutaneous retrobulbar amphotericin-B. The mean follow-up duration was 5.62 ± 0.78 months (median 6). Favorable outcome was seen in 35 (60%) cases. Presence of uncontrolled diabetes (p = 0.001), orbital apex involvement (p = 0.04), CNS involvement (p = 0.04), and history of steroid use (p < 0.0001) resulted in unfavorable outcome. CNS involvement was the only factor predicting mortality (p = 0.03). Mortality was seen in 20 (34%) patients. Conclusion: Over a third of patients with rhino-orbital-cerebral mucormycosis following COVID-19 have an unfavorable clinical outcome. Uncontrolled diabetes mellitus at presentation, involvement of the orbital apex, CNS, and the usage of steroids were associated with poorer outcomes. CNS involvement was a factor determining mortality.Keywords
This publication has 37 references indexed in Scilit:
- Mucormycosis of the head and neck: Report of five cases with different presentationsJournal of Cranio-Maxillofacial Surgery, 2012
- Rhino-Orbital-Cerebral MucormycosisCurrent Infectious Disease Reports, 2012
- Rhinocerebral mucormycosis: experience in 14 patientsThe Journal of Laryngology & Otology, 2011
- Rhinocerebral Mucormycosis: Consideration of prognostic factors and treatment modalityAuris Nasus Larynx, 2009
- Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral MucormycosisClinical Infectious Diseases, 2008
- Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and ManagementClinical Microbiology Reviews, 2005
- Improving outcomes in rhinocerebral mucormycosis - early diagnostic pointers and prognostic factorsThe Journal of Laryngology & Otology, 2003
- Ten Years' Experience in Zygomycosis at a Tertiary Care Centre in IndiaJournal of Infection, 2001
- In Vivo Bronchoalveolar Macrophage Defense Against Rhizopus oryzae and Aspergillus fumigatusThe Journal of Infectious Diseases, 1984
- Diagnosis and Management of Rhino-Orbitocerebral Mucormycosis (Phycomycosis)Ophthalmology, 1983